Breaking News Instant updates and real-time market news.

APVO

Aptevo Therapeutics

$6.18 /

+0.34 (+5.82%)

, PDDPF

Medexus

$0.00 /

+ (+0.00%)

08:56
05/22/20
05/22
08:56
05/22/20
08:56

Medexus reports Q4 preliminary unaudited sales for IXINITY of $8.3M

Medexus Pharmaceuticals (PDDPF) provided an update on its business in light of the recent transformative acquisition of the commercial hematology asset, IXINITY, the resulting re-organization and alignment of Medexus' U.S.-based business and the Company's ongoing response to the COVID-19 pandemic. With the Company's acquisition of Aptevo BioTherapeutics (APVO), which owns the IXINITY asset, from Aptevo Therapeutics having closed on February 28, 2020, the fiscal fourth quarter ending March 31, 2020 is the first quarter that includes revenue for Medexus from sales of IXINITY. On May 13, 2020, Aptevo announced its financial results for its quarter ended March 31, 2020, which included two months of pre-Acquisition sales of IXINITY by Aptevo and one post-Acquisition month of the 2% royalty Medexus pays to Aptevo on sales of IXINITY by Medexus. Aggregate preliminary unaudited sales estimates for IXINITY during Q4 2020 totaled $8.3M, which represents an 18.5% year over year increase. Approximately 85% of those IXINITY sales accrued to the benefit of Medexus post-Acquisition and as such, the addition of IXINITY was highly accretive to Medexus for the quarter. The revenues from IXINITY for March 2020 are in line with the Company's expectations, including that the majority of the quarterly revenue from IXINITY would be recognized in the final month of Q4 2020. The Company expects to announce its full audited financial results for Q4 2020 and for the fiscal year ended March 31, 2020 in the normal course before the end of June 2020, but the Company felt it was important to provide this context to its shareholders in light of the disclosures provided by Aptevo and given the timing and impact to the Company of the Acquisition. The integration of IXINITY is progressing in line with the Company's expectations, and the Company sees significant potential for further growth in sales of the product as the Company leverages its integrated and expanded sales force in the U.S. As part of the integration process, effective immediately, Michael Adelman has been appointed as the General Manager of Medexus' U.S. operations. Mr. Adelman joined Medexus from Aptevo immediately following the completion of the Acquisition. Also effective immediately, Terri Shoemaker will no longer serve as the Company's President, U.S. Operations. As announced on May 7, 2020, the Company also completed its financing package with MidCap Financial Trust in respect of a secured asset-based revolving credit facility having a term of 38 months. The ABL Facility features a $20M revolving commitment and uncommitted $10M accordion. Borrowings under the ABL Facility bear interest at a rate of one-month LIBOR plus 3.95%, subject to a LIBOR floor of 1.50%. The financing package with MidCap Financial allowed the Company to finance the Acquisition without the issuance of additional shares of the Company. Finally, the Company continues to work diligently to assess and address the risks and operational challenges posed by the COVID-19 pandemic. While the situation continues to evolve, the Company believes it has largely been successful in conducting business as usual to the extent possible. To date, none of the Company's employees have reported testing positive for the COVID-19 virus, and management continues to carefully monitor the Company's supply and downstream network. Medexus' supply chain remains secure and the Company is not aware of any disruption to the supply of any of its products to the patients who depend on them.

APVO

Aptevo Therapeutics

$6.18 /

+0.34 (+5.82%)

PDDPF

Medexus

$0.00 /

+ (+0.00%)

  • 27

    May

APVO Aptevo Therapeutics
$6.18 /

+0.34 (+5.82%)

05/14/20 Piper Sandler
Aptevo Therapeutics price target lowered to $18.50 from $24 at Piper Sandler
03/25/20 Piper Sandler
Aptevo Therapeutics has $30M in cash, says Piper Sandler
03/16/20 Piper Sandler
Aptevo could report APVO436 cohort 5 data at ASH in December, says Piper Sandler
03/04/20 Roth Capital
Aptevo Therapeutics assumed with a Buy at Roth Capital
PDDPF Medexus
$0.00 /

+ (+0.00%)

03/27/20 Canaccord
Medexus downgraded to Speculative Buy from Buy at Canaccord

TODAY'S FREE FLY STORIES

Recommendations
Anaplan price target raised to $55 from $50 at Deutsche Bank » 07:36
05/27/20
05/27
07:36
05/27/20
07:36
PLAN

Anaplan

/

+

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PLAN Anaplan
/

+

PLAN Anaplan
/

+

06:48 Today Mizuho
Anaplan price target raised to $58 from $50 at Mizuho
05/26/20 Piper Sandler
Anaplan price target raised to $51 from $38 at Piper Sandler
05/26/20 Piper Sandler
Piper Sandler would be buyers on Anaplan weakness following earnings
05/26/20 Goldman Sachs
Anaplan should benefit as macro situation improves, says Goldman Sachs
PLAN Anaplan
/

+

PLAN Anaplan
/

+

PLAN Anaplan
/

+

Downgrade
Hyatt downgraded to Neutral at Baird » 07:36
05/27/20
05/27
07:36
05/27/20
07:36
H

Hyatt

$56.39 /

+3.79 (+7.21%)

As reported previously,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
H Hyatt
$56.39 /

+3.79 (+7.21%)

H Hyatt
$56.39 /

+3.79 (+7.21%)

05:35 Today Baird
Hyatt downgraded to Neutral from Outperform at Baird
05/08/20
Fly Intel: Top five analyst downgrades
05/08/20 Deutsche Bank
Hyatt price target lowered to $54 from $86 at Deutsche Bank
05/08/20 Macquarie
Hyatt downgraded to Neutral from Outperform at Macquarie
H Hyatt
$56.39 /

+3.79 (+7.21%)

H Hyatt
$56.39 /

+3.79 (+7.21%)

H Hyatt
$56.39 /

+3.79 (+7.21%)

H Hyatt
$56.39 /

+3.79 (+7.21%)

Hot Stocks
MacroGenics announces registration study of flotetuzumab in refractory AML » 07:35
05/27/20
05/27
07:35
05/27/20
07:35
MGNX

MacroGenics

$23.64 /

-1.71 (-6.75%)

MacroGenics announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MGNX MacroGenics
$23.64 /

-1.71 (-6.75%)

MGNX MacroGenics
$23.64 /

-1.71 (-6.75%)

05/26/20 H.C. Wainwright
MacroGenics price target raised to $40 from $22 at H.C. Wainwright
05/14/20 Wedbush
MacroGenics price target raised to $28 from $16 at Wedbush
05/12/20 Credit Suisse
MacroGenics price target raised to $30 from $13 at Credit Suisse
05/06/20 H.C. Wainwright
MacroGenics price target raised to $22 from $18 at H.C. Wainwright
MGNX MacroGenics
$23.64 /

-1.71 (-6.75%)

MGNX MacroGenics
$23.64 /

-1.71 (-6.75%)

General news
European Commission forwards proposal for EUR 750B 'Next Generation EU' plan » 07:35
05/27/20
05/27
07:35
05/27/20
07:35
SPY

SPDR S&P 500 ETF Trust

$299.25 /

+3.83 (+1.30%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

The European Commission…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$299.25 /

+3.83 (+1.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$299.25 /

+3.83 (+1.30%)

03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
12/16/19 Piper Jaffray
Piper establishes 2020 S&P 500 price objective of 3,600
SPX S&P 500
$0.00 /

+ (+0.00%)

03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
12/16/19 Piper Jaffray
Piper establishes 2020 S&P 500 price objective of 3,600
SPY SPDR S&P 500 ETF Trust
$299.25 /

+3.83 (+1.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$299.25 /

+3.83 (+1.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$299.25 /

+3.83 (+1.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$299.25 /

+3.83 (+1.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

SPY SPDR S&P 500 ETF Trust
$299.25 /

+3.83 (+1.30%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Recommendations
Acadia price target raised to $53 from $48 at Oppenheimer » 07:33
05/27/20
05/27
07:33
05/27/20
07:33
ACAD

Acadia

$51.16 /

-0.09 (-0.18%)

Oppenheimer analyst Jay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACAD Acadia
$51.16 /

-0.09 (-0.18%)

ACAD Acadia
$51.16 /

-0.09 (-0.18%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
ACAD Acadia
$51.16 /

-0.09 (-0.18%)

ACAD Acadia
$51.16 /

-0.09 (-0.18%)

ACAD Acadia
$51.16 /

-0.09 (-0.18%)

Hot Stocks
vTv Therapeutics to present results from Phase 2 Simplici-T1 study of TTP399 » 07:33
05/27/20
05/27
07:33
05/27/20
07:33
VTVT

vTv Therapeutics

$2.89 /

-0.03 (-1.03%)

vTv Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VTVT vTv Therapeutics
$2.89 /

-0.03 (-1.03%)

VTVT vTv Therapeutics
$2.89 /

-0.03 (-1.03%)

02/10/20 H.C. Wainwright
vTv Therapeutics price target raised to $6 from $5 at H.C. Wainwright
05/30/19 H.C. Wainwright
vTv Therapeutics initiated with a Buy at H.C. Wainwright
VTVT vTv Therapeutics
$2.89 /

-0.03 (-1.03%)

Downgrade
Latam Airlines downgraded to Sell from Hold at Deutsche Bank » 07:33
05/27/20
05/27
07:33
05/27/20
07:33
LTM

Latam Airlines

/

+

, AVH

Avianca

$0.87 /

+ (+0.00%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LTM Latam Airlines
/

+

AVH Avianca
$0.87 /

+ (+0.00%)

LTM Latam Airlines
/

+

05/26/20 Raymond James
Latam Airlines downgraded to Underperform from Outperform at Raymond James
05/04/20 Deutsche Bank
Avianca downgraded to Sell from 50c price target at Deutsche Bank
04/24/20 Morgan Stanley
Latam Airlines downgraded to Underweight from Equal Weight at Morgan Stanley
04/16/20 HSBC
Latam Airlines upgraded to Buy from Hold at HSBC
AVH Avianca
$0.87 /

+ (+0.00%)

05/12/20 Citi
Avianca downgraded to Sell from Neutral at Citi
05/04/20 Deutsche Bank
Avianca downgraded to Sell from 50c price target at Deutsche Bank
05/04/20 Deutsche Bank
Avianca downgraded to Sell from Hold at Deutsche Bank
04/13/20 Bradesco
Avianca downgraded to Underperform from Neutral at Bradesco
LTM Latam Airlines
/

+

AVH Avianca
$0.87 /

+ (+0.00%)

LTM Latam Airlines
/

+

LTM Latam Airlines
/

+

Recommendations
Qualcomm reiterates 2020 will be 'year of 5G". says Cowen » 07:33
05/27/20
05/27
07:33
05/27/20
07:33
QCOM

Qualcomm

$77.98 /

-0.78 (-0.99%)

Cowen analyst Matthew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
QCOM Qualcomm
$77.98 /

-0.78 (-0.99%)

QCOM Qualcomm
$77.98 /

-0.78 (-0.99%)

05/21/20 Canaccord
Qualcomm strongly positioned for 5G investment cycle, says Canaccord
05/18/20 Wedbush
Apple yet again caught in U.S./China Tensions, says Wedbush
05/04/20
Fly Intel: Top five analyst initiations
05/04/20 KeyBanc
Apple cautious iPhone outlook likely a headwind for chip suppliers, says KeyBanc
QCOM Qualcomm
$77.98 /

-0.78 (-0.99%)

QCOM Qualcomm
$77.98 /

-0.78 (-0.99%)

QCOM Qualcomm
$77.98 /

-0.78 (-0.99%)

QCOM Qualcomm
$77.98 /

-0.78 (-0.99%)

Hot Stocks
Arcus Biosciences down 10% after announcing a 10-year partnership with Gilead » 07:32
05/27/20
05/27
07:32
05/27/20
07:32
RCUS

Arcus Biosciences

$33.51 /

-2.35 (-6.55%)

, GILD

Gilead

$73.14 /

-0.17 (-0.23%)

Gilead (GILD) is down…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
GILD Gilead
$73.14 /

-0.17 (-0.23%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/26/20 SunTrust
Gilead upgraded to Hold at SunTrust on remdesivir commercial prospects
05/26/20 SunTrust
Gilead upgraded to Hold from Sell at SunTrust
05/26/20 Piper Sandler
Piper Sandler encouraged by remdesivir results published in NEJM
RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

Hot Stocks
Equitable to work with BlackRock to provide lifetime income thorough an annuity » 07:32
05/27/20
05/27
07:32
05/27/20
07:32
EQH

Equitable Holdings

$19.21 /

+1.495 (+8.44%)

, BLK

BlackRock

$523.62 /

+10.56 (+2.06%)

Equitable, a subsidiary…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EQH Equitable Holdings
$19.21 /

+1.495 (+8.44%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

EQH Equitable Holdings
$19.21 /

+1.495 (+8.44%)

04/17/20 Citi
Equitable Holdings upgraded to Buy from Neutral at Citi
04/01/20 Credit Suisse
AXA Equitable upgraded to Outperform from Neutral at Credit Suisse
03/20/20 RBC Capital
RBC Capital sees some time before Life Insurance returns to 'normal'
03/20/20 RBC Capital
AXA Equitable downgraded to Sector Perform from Outperform at RBC Capital
BLK BlackRock
$523.62 /

+10.56 (+2.06%)

05/14/20 Wells Fargo
BlackRock price target raised to $530 from $495 at Wells Fargo
05/12/20 Stephens
PNC Financial upgraded to Overweight from Equal Weight at Stephens
04/17/20 BMO Capital
BlackRock price target raised to $441 from $386 at BMO Capital
04/17/20 Barclays
BlackRock price target raised to $515 from $495 at Barclays
EQH Equitable Holdings
$19.21 /

+1.495 (+8.44%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

Hot Stocks
Cytokinetics renews partnership with The ALS Association » 07:31
05/27/20
05/27
07:31
05/27/20
07:31
CYTK

Cytokinetics

$21.86 /

-0.06 (-0.27%)

Cytokinetics,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CYTK Cytokinetics
$21.86 /

-0.06 (-0.27%)

CYTK Cytokinetics
$21.86 /

-0.06 (-0.27%)

05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
05/11/20 Piper Sandler
Piper boosts Cytokinetics target to $28 on positive MyoKardia read-through
05/05/20
Fly Intel: Top five analyst initiations
05/04/20
Cytokinetics initiated with a Buy at Mizuho
CYTK Cytokinetics
$21.86 /

-0.06 (-0.27%)

CYTK Cytokinetics
$21.86 /

-0.06 (-0.27%)

Upgrade
AMC Entertainment upgraded to Neutral from Sell at MKM Partners » 07:31
05/27/20
05/27
07:31
05/27/20
07:31
AMC

AMC Entertainment

$5.10 /

+0.53 (+11.60%)

MKM Partners analyst Eric…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMC AMC Entertainment
$5.10 /

+0.53 (+11.60%)

AMC AMC Entertainment
$5.10 /

+0.53 (+11.60%)

05:39 Today MKM Partners
AMC Entertainment upgraded to Neutral from Sell at MKM Partners
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
05/11/20 B. Riley FBR
Amazon buyout may not appeal to AMC shareholders, says B. Riley FBR
04/30/20 Imperial Capital
AMC Entertainment price target raised to $3 from $2 at Imperial Capital
AMC AMC Entertainment
$5.10 /

+0.53 (+11.60%)

AMC AMC Entertainment
$5.10 /

+0.53 (+11.60%)

AMC AMC Entertainment
$5.10 /

+0.53 (+11.60%)

AMC AMC Entertainment
$5.10 /

+0.53 (+11.60%)

Recommendations
Tractor Supply price target raised to $135 from $110 at Oppenheimer » 07:30
05/27/20
05/27
07:30
05/27/20
07:30
TSCO

Tractor Supply

$111.19 /

-0.73 (-0.65%)

Oppenheimer analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

06:29 Today Stephens
Tractor Supply price target raised to $135 from $110 at Stephens
06:28 Today Nomura Instinet
Tractor Supply price target raised to $110 from $95 at Nomura Instinet
06:11 Today Piper Sandler
Tractor Supply price target raised to $130 from $114 at Piper Sandler
05/26/20 Baird
Tractor Supply price target raised to $130 from $115 at Baird
TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

Hot Stocks
Gilead receives right to opt-in to all other programs in Arcus portfolio » 07:30
05/27/20
05/27
07:30
05/27/20
07:30
GILD

Gilead

$73.14 /

-0.17 (-0.23%)

, RCUS

Arcus Biosciences

$33.51 /

-2.35 (-6.55%)

Gilead (GILD) and Arcus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/26/20 SunTrust
Gilead upgraded to Hold at SunTrust on remdesivir commercial prospects
05/26/20 SunTrust
Gilead upgraded to Hold from Sell at SunTrust
05/26/20 Piper Sandler
Piper Sandler encouraged by remdesivir results published in NEJM
RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

Hot Stocks
Brighthouse Financial chosen to help deliver BlackRock LifePath Paycheck » 07:29
05/27/20
05/27
07:29
05/27/20
07:29
BHF

Brighthouse Financial

$31.55 /

+2.78 (+9.66%)

, BLK

BlackRock

$523.62 /

+10.56 (+2.06%)

Brighthouse Financial…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BHF Brighthouse Financial
$31.55 /

+2.78 (+9.66%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

BHF Brighthouse Financial
$31.55 /

+2.78 (+9.66%)

05/13/20 RBC Capital
Brighthouse Financial price target raised to $33 from $24 at RBC Capital
04/27/20 Credit Suisse
Brighthouse Financial price target lowered to $34 from $45 at Credit Suisse
04/01/20 Wells Fargo
Brighthouse Financial price target lowered to $29 from $37 at Wells Fargo
03/20/20 RBC Capital
Brighthouse Financial price target lowered to $24 from $50 at RBC Capital
BLK BlackRock
$523.62 /

+10.56 (+2.06%)

05/14/20 Wells Fargo
BlackRock price target raised to $530 from $495 at Wells Fargo
05/12/20 Stephens
PNC Financial upgraded to Overweight from Equal Weight at Stephens
04/17/20 BMO Capital
BlackRock price target raised to $441 from $386 at BMO Capital
04/17/20 Barclays
BlackRock price target raised to $515 from $495 at Barclays
BHF Brighthouse Financial
$31.55 /

+2.78 (+9.66%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

BLK BlackRock
$523.62 /

+10.56 (+2.06%)

Hot Stocks
Allstate extends shelter-in-place payback for auto customers through June 30 » 07:27
05/27/20
05/27
07:27
05/27/20
07:27
ALL

Allstate

$94.08 /

-0.725 (-0.76%)

In a regulatory 8-K…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALL Allstate
$94.08 /

-0.725 (-0.76%)

ALL Allstate
$94.08 /

-0.725 (-0.76%)

05/06/20 JPMorgan
Allstate results affirm bullish view, says JPMorgan
04/21/20 Raymond James
Allstate price target raised to $120 from $110 at Raymond James
04/20/20 SunTrust
Valvoline price target lowered to $16 from $23 at SunTrust
04/13/20 Evercore ISI
Allstate upgraded to Outperform from In Line at Evercore ISI
ALL Allstate
$94.08 /

-0.725 (-0.76%)

Recommendations
Repligen price target raised to $150 from $135 at Stifel » 07:27
05/27/20
05/27
07:27
05/27/20
07:27
RGEN

Repligen

$133.29 /

-6.18 (-4.43%)

Stifel analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RGEN Repligen
$133.29 /

-6.18 (-4.43%)

RGEN Repligen
$133.29 /

-6.18 (-4.43%)

05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
03/23/20 H.C. Wainwright
Repligen price target lowered to $100 from $110 at H.C. Wainwright
11/14/19 Stifel
Repligen initiated with a Buy at Stifel
RGEN Repligen
$133.29 /

-6.18 (-4.43%)

Downgrade
Acushnet Holdings downgraded to Neutral at Roth Capital after strong run » 07:26
05/27/20
05/27
07:26
05/27/20
07:26
GOLF

Acushnet Holdings

$32.55 /

+1.37 (+4.39%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GOLF Acushnet Holdings
$32.55 /

+1.37 (+4.39%)

GOLF Acushnet Holdings
$32.55 /

+1.37 (+4.39%)

07:22 Today Roth Capital
Acushnet Holdings downgraded to Neutral from Buy at Roth Capital
05/19/20 Stephens
Data points to 'encouraging signs' of golf industry demand, says Stephens
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 Compass Point
With half of U.S. golf courses closed, Compass Point cuts Acushnet to Sell
GOLF Acushnet Holdings
$32.55 /

+1.37 (+4.39%)

Hot Stocks
Gilead will have the right to appoint 2 individuals to Arcus board after deal  07:24
05/27/20
05/27
07:24
05/27/20
07:24
GILD

Gilead

$73.14 /

-0.17 (-0.23%)

, RCUS

Arcus Biosciences

$33.51 /

-2.35 (-6.55%)

 
ShowHide Related Items >><<
GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/26/20 SunTrust
Gilead upgraded to Hold at SunTrust on remdesivir commercial prospects
05/26/20 SunTrust
Gilead upgraded to Hold from Sell at SunTrust
05/26/20 Piper Sandler
Piper Sandler encouraged by remdesivir results published in NEJM
RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

Conference/Events
GATX participates in a conference call hosted by Sidoti » 07:23
05/27/20
05/27
07:23
05/27/20
07:23
GATX

GATX

$62.11 /

+0.055 (+0.09%)

Conference call with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GATX GATX
$62.11 /

+0.055 (+0.09%)

GATX GATX
$62.11 /

+0.055 (+0.09%)

GATX GATX
$62.11 /

+0.055 (+0.09%)

Recommendations
PagSeguro Digital price target raised to $32 from $20 at KeyBanc » 07:23
05/27/20
05/27
07:23
05/27/20
07:23
PAGS

PagSeguro Digital

$28.06 /

+1.805 (+6.87%)

KeyBanc analyst Josh Beck…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PAGS PagSeguro Digital
$28.06 /

+1.805 (+6.87%)

05/05/20 Itau BBA
PagSeguro Digital downgraded to Market Perform from Outperform at Itau BBA
04/28/20 Deutsche Bank
PagSeguro Digital price target lowered to $30 from $52 at Deutsche Bank
03/23/20 KeyBanc
PagSeguro Digital price target lowered to $20 from $35 at KeyBanc
02/28/20 Cantor Fitzgerald
PagSeguro Digital price target lowered to $39 from $46 at Cantor Fitzgerald
PAGS PagSeguro Digital
$28.06 /

+1.805 (+6.87%)

Hot Stocks
Gilead to make $200M equity investment in Arcus at a price of $33.54 per share » 07:23
05/27/20
05/27
07:23
05/27/20
07:23
GILD

Gilead

$73.14 /

-0.17 (-0.23%)

, RCUS

Arcus Biosciences

$33.51 /

-2.35 (-6.55%)

Gilead (GILD) and Arcus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/26/20 SunTrust
Gilead upgraded to Hold at SunTrust on remdesivir commercial prospects
05/26/20 SunTrust
Gilead upgraded to Hold from Sell at SunTrust
05/26/20 Piper Sandler
Piper Sandler encouraged by remdesivir results published in NEJM
RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

Downgrade
Acushnet Holdings downgraded to Neutral from Buy at Roth Capital » 07:22
05/27/20
05/27
07:22
05/27/20
07:22
GOLF

Acushnet Holdings

$32.55 /

+1.37 (+4.39%)

Roth Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GOLF Acushnet Holdings
$32.55 /

+1.37 (+4.39%)

GOLF Acushnet Holdings
$32.55 /

+1.37 (+4.39%)

05/19/20 Stephens
Data points to 'encouraging signs' of golf industry demand, says Stephens
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 Compass Point
With half of U.S. golf courses closed, Compass Point cuts Acushnet to Sell
04/21/20 Compass Point
Acushnet Holdings downgraded to Sell from Neutral at Compass Point
GOLF Acushnet Holdings
$32.55 /

+1.37 (+4.39%)

Recommendations
Twilio price target raised to $240 from $180 at RBC Capital » 07:22
05/27/20
05/27
07:22
05/27/20
07:22
TWLO

Twilio

$195.97 /

-12.67 (-6.07%)

RBC Capital analyst Alex…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TWLO Twilio
$195.97 /

-12.67 (-6.07%)

TWLO Twilio
$195.97 /

-12.67 (-6.07%)

05/26/20 Needham
Twilio price target raised to $225 from $170 at Needham
05/20/20 JMP Securities
Twilio price target raised to $200 from $160 at JMP Securities
05/07/20 DA Davidson
Twilio price target raised to $175 from $144 at DA Davidson
05/07/20 Wells Fargo
Twilio price target raised to $175 from $140 at Wells Fargo
TWLO Twilio
$195.97 /

-12.67 (-6.07%)

TWLO Twilio
$195.97 /

-12.67 (-6.07%)

TWLO Twilio
$195.97 /

-12.67 (-6.07%)

TWLO Twilio
$195.97 /

-12.67 (-6.07%)

Hot Stocks
Gilead, Arcus Biosciences establish 10-year cancer immunotherapies partnership » 07:20
05/27/20
05/27
07:20
05/27/20
07:20
GILD

Gilead

$73.14 /

-0.17 (-0.23%)

, RCUS

Arcus Biosciences

$33.51 /

-2.35 (-6.55%)

Gilead Sciences (GILD)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/26/20 SunTrust
Gilead upgraded to Hold at SunTrust on remdesivir commercial prospects
05/26/20 SunTrust
Gilead upgraded to Hold from Sell at SunTrust
05/26/20 Piper Sandler
Piper Sandler encouraged by remdesivir results published in NEJM
RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
05/06/20 Wedbush
Arcus Biosciences price target raised to $40 from $26 at Wedbush
04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

GILD Gilead
$73.14 /

-0.17 (-0.23%)

RCUS Arcus Biosciences
$33.51 /

-2.35 (-6.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.